NEW YORK (GenomeWeb) – Response Genetics has filed a shelf registration with the US Securities and Exchange Commission to offer up to $20 million in securities from time to time.

Securities that may be offered include Response's common stock, preferred stock, and warrants, the company said in its SEC document. Proceeds from any offering will go toward general corporate purposes, such as the funding of its operations, working capital, R&D efforts, capital expenditures, and strategic investments.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.